Month: September 2016

The number of uninsured people in the U.S. remained at a historic low in early 2016, according to a federal survey that found 8.6% of respondents without health coverage at the time of the interview.

President Barack Obama made a personal bid Monday to shore up his signature health law as it heads into its final test of his administration, urging insurers selling plans on HealthCare.gov to stay the course and pledging redoubled efforts by the government to make the law a success.

Reaching out to a past opponent can be difficult, but it can also be rewarding. It’s important to remember that people and organizations can change. A rival from childhood could become a good friend later in life. A former competitor could be your future business partner. Old attitudes fade because they need to change. It’s a new world to grow your business, ...

Significant spikes in premiums, insurer dropouts and persistently low enrollment numbers are combining to make this fall’s sign-up period a crossroads for the Obama administration’s signature health law.

Rising drug costs are often blamed for driving up health insurance premiums, but a major consumer group says the numbers don’t add up — at least in California.

Federal officials continue to make operational adjustments in the health law marketplaces and meet with some insurers to encourage them to offer more plans in areas of the country that are forecast to be low on competition following the withdrawal of some major insurers for 2017, Department of Health and Human Services Secretary Sylvia Burwell said Thursday.

The CMS' plan to eliminate Medicare payments for new off-campus outpatient departments has kicked up fierce opposition from hospitals. As the comment period comes to a close, hospitals argue it threatens not just lost revenue but also substantial and unavoidable legal risks.

Cal INDEX, a highly touted database of patient medical records backed by two of California’s largest health insurers, is searching for a new chief executive as it tries to overcome a slow start.

Following weeks of criticism over dramatic price increases on its EpiPen, Mylan said Monday it will offer a generic version of the life-saving allergy treatment.

At least eight pharmaceutical companies sell a decades-old drug that treats gallstones, but the competition has done little to keep its price down.